What is esketamine and how does it treat depression?
Spray containing ketamine-related chemical hailed as ‘breakthrough’ but side effects spark concerns
A controversial new nasal spray containing a substance related to ketamine has been approved for use in patients with severe depression by the US Food and Drug Administration (FDA).
Spravato, the brand name for an esketamine nasal spray, was given the green light by the US regulator this week - albeit with strict conditions. The spray can be prescribed, in conjunction with an oral antidepressant, for adults who have tried other treatments unsucessfully - a condition known as treatment-resistant depression, says the FDA.
The European Medicines Agency is also considering a licence application that, if approved, would pave the way for the medication to be offered on the NHS.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
But while commentators including The Independent have described the drug as a potential “breakthrough” for patients suffering persistent depression, others have raised concerns about the risks of the party drug’s chemical cousin.
So what is the new spray and how does it work?
What is esketamine?
Esketamine is a general anesthaetic that can be administered either as a nasal spray or intravenously.
In the case of Spravato, the esketamine will be administered as a nasal spray in the US by an approved health care provider in a doctor’s office or a medical clinic.
The Guardian notes that the drug “builds on years of research” into ketamine, to which esketamine is closely related, as a treatment for major depression. ABC News adds that some doctors “have given ketamine to people with depression without formal FDA approval”.
Both ketamine and esketamine work differently to commonly prescribed antidepressants such as citalopram and sertraline, which bump up levels of feel-good brain chemical serotonin.
By contrast, Esketamine targets glutamate, a neurotransmitter that sends messages across the brain. “Research has shown people with depression also tend to have an overabundance of glutamate,” says Gizmodo.
Does it work?
Various clinical trials suggest esketamine “is up to ten times more effective than current drugs in people suffering from treatment-resistant depression”, says The Daily Telegraph.
In one study submitted to the FDA as evidence, more than 70% of 101 patients who took esketamine reported a 50% or more reduction in their depression symptoms, says Psychology Today.
Soonjo Hwang, a psychiatrist with the University of Nebraska Medical Center, told Health magazine: “People are saying this is a game changer because it seems like it works well for refractory depression, meaning people who have failed to respond to conventional antidepressant medications and behavioural treatments.
“Also, it seems to work in 24 to 48 hours, so there’s a very rapid resolution of symptoms.”
These rapid effects could be especially helpful in treating patients at high risk of committing suicide or self-harm.
Timothy Sullivan, chair of psychiatry and behavioral science at New York’s Staten Island University Hospital, said that “anything that promises to help address the needs” of people with chronic severe depression was “really exciting”.
What about the drawbacks?
The FDA notes that esketamine comes with a “risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato administration”, along with “potential for abuse and misuse of the drug”. As a result, its usage will be strictly limited.
Side effects include “dizziness, nausea, vertigo, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, decreased sensitivity, sedation and dissociation, a feeling of being temporarily ‘disconnected’ from your body and your mind”, reports CNN.
Because of these risks, patients can only be given the drug in registered clinics and must be monitored for at least two hours afterwards by a medical professional. They cannot take the drug home and are not allowed to drive for the rest of that day.
The Verge reports that packets of esketamine “will carry the FDA’s gravest warning - a black box that says there’s potential for this drug to be abused”. Potential users will also be warned that the drug may cause suicidal thoughts.
It’s currently unclear how widely US insurance companies will cover esketamine, which costs between $4,720 (£3,610) and $6,785 (£5,190) for the first month of treatment alone, adds The Guardian.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
5 highly educational cartoons about student protests
Cartoons Artists take on apolitical camping, the National Guard, and more
By The Week US Published
-
French schools and the scourge of teenage violence
Talking Point Gabriel Attal announces 'bold' intervention to tackle rise in violent incidents
By The Week UK Published
-
On the trail of India’s wild lions at Sasan Gir National Park
The Week Recommends The sanctuary is a 'roaring' conservation success
By The Week UK Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
Narcan is becoming harder to find at drugstores across America
Under the Radar The drug, also known as naloxone, reverses the effects of an opioid overdose
By Justin Klawans, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
The lows of an unregulated high: Teens are using marijuana alternative delta-8
In the Spotlight More than 1 in 10 high school seniors have reported using the substance, which contains concentrated THC
By Justin Klawans, The Week US Published
-
How helpful are mental health apps?
Under the radar Market is booming, offering accessibility and affordability, but many apps are unregulated and share sensitive user data
By Harriet Marsden, The Week UK Published
-
How the transmission of Alzheimer's might be possible
The Explainer New research links dementia cases to injections of human growth hormone from deceased donors' brains
By Chas Newkey-Burden, The Week UK Published
-
Car fatality rates are driving up
The Explainer The dang Covid pandemic made us worse drivers
By Devika Rao, The Week US Published
-
Tianeptine: why lawmakers fear a new kind of opioid
The explainer The drug is sold over the counter. And is highly addictive.
By Devika Rao, The Week US Published